Laurus Labs Limited Bombay S.E.

LAURUSLABS

INE947Q01028

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:55 2024-06-27 EDT			5-day change	1st Jan Change
423.8 ^INR	-0.82%		-2.06%	-1.49%

06-26	Willow Biosciences Provides Corporate Update and Signs New Partnered Program	MT
06-26	Willow Biosciences Brief: Announced multi-product development and licensing partnership with Laurus Labs for manufacturing active pharmaceutical ingredients	MT

Laurus Labs Limited Announces Resignation of Mr. Conner Town Mulvee from the Board

January 02, 2017 at 09:44 am

Laurus Labs Limited announced that Mr. Conner Town Mulvee, the Nominee Director of Aptuit, has tendered his resignation from the Board of the Company with immediate effect.

Latest news about Laurus Labs Limited

Willow Biosciences Provides Corporate Update and Signs New Partnered Program	06-26	MT
Willow Biosciences Brief: Announced multi-product development and licensing partnership with Laurus Labs for manufacturing active pharmaceutical ingredients	06-26	MT
CARE Affirms AA Rating on Laurus Labs' Long-term Bank Financing; Revises Outlook to Negative	06-18	MT
Willow Biosciences Signs Multi-Product Development, Licensing Partnership With Laurus Lab	05-30	MT
Willow Biosciences Inc. Announces Multi-Product Development and Licensing Partnership with Laurus Labs	05-30	CI
Granules India posts Q4 revenue fall on weak paracetamol sales, price erosion	05-15	RE
Transcript : Laurus Labs Limited, Q4 2024 Earnings Call, Apr 25, 2024	04-25
Laurus Labs' Consolidated Profit Falls in Fiscal Q4	04-25	MT
Laurus Labs Limited Approves Second Interim Dividend for the Financial Year 2023-2024, Payable on or After May 17, 2024	04-25	CI
Laurus Labs Limited Approves Board Changes	04-25	CI
Laurus Labs Limited Reports Earnings Results for the Full Year Ended March 31, 2024	04-25	CI
Laurus Labs Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	04-25	CI
Laurus Labs Board to Consider Second Interim Dividend for Fiscal Year 2024	04-18	MT
Laurus Labs Incorporates New JV Company with Slovenia-Based Pharmaceutical Company	04-15	MT
Laurus Labs, Slovenia's Krka to Form JV; Laurus Shares Fall 6%	01-26	MT
Laurus Labs Limited Reaches to Agreement with Krka to Establish Joint Venture Company in Hyderabad, India Namely Krka Pharma Pvt. Ltd	01-25	CI
Jefferies Adjusts Laurus Labs’ Price Target to INR250 From INR290, Keeps at Underperform	01-25	MT
Laurus Labs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	01-24	CI
Transcript : Laurus Labs Limited, Q3 2024 Earnings Call, Jan 24, 2024	01-24
INDIA STOCKS-IT drives losses in Indian shares ahead of Fed policy outcome	12-12	RE
Indian shares set to open higher; focus turns to Fed policy	12-12	RE
Laurus Labs Completes Acquisition of Additional Stake in Laurus Bio	11-21	MT
Laurus Labs Limited completed the acquisition of additional 14.54% stake in Laurus Bio Private Limited from one of the Promoters, non-executive director, his family members and few Employee/ex-Employee shareholders.	11-19	CI
Jefferies Adjusts Laurus Labs’ Price Target to INR260 From INR250, Keeps at Underperform	23-10-23	MT
Laurus Labs Limited Announces Resignation of Chandrakanth Chereddi as Non-Executive Director	23-10-20	CI

Laurus Labs Limited is an India-based pharmaceutical and biotechnology company. The Company offers integrated portfolio of Active Pharma Ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry. The Company operates through three segments: Laurus Generics, Laurus Synthesis, and Laurus Bio. The Laurus Generics segment comprises API and FDF-Development, manufacture and sale of APIs and advanced intermediates and oral solid formulations/FDF. Laurus Synthesis segment comprises key starting materials (KSM), intermediates and APIs for new chemical entities (NCEs). Laurus Bio segment comprises recombinant products, animal origin free products for safer and viral free bio manufacturing. The Company operates through two geographical segments: Revenue from customers within India-Domestic, and Revenue from customers outside India-Exports. The Company sell its APIs in 56 countries.

Sector

Pharmaceuticals

Calendar

2024-07-11 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Laurus Labs Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

427.4 INR

Average target price

393.4 INR

Spread / Average Target

-7.97%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+54.61%	811B
NOVO NORDISK A/S	+43.30%	640B
JOHNSON & JOHNSON	-6.33%	353B
MERCK & CO., INC.	+20.62%	333B
ABBVIE INC.	+10.44%	302B
ASTRAZENECA PLC	+17.89%	246B
ROCHE HOLDING AG	+2.41%	225B
NOVARTIS AG	+12.58%	218B
AMGEN INC.	+8.61%	168B

Other Pharmaceuticals

Laurus Labs Limited Bombay S.E.

Equities

LAURUSLABS

INE947Q01028

Pharmaceuticals

Laurus Labs Limited Announces Resignation of Mr. Conner Town Mulvee from the Board

Latest news about Laurus Labs Limited

Chart Laurus Labs Limited

Company Profile

Income Statement Evolution

Ratings for Laurus Labs Limited

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals